Associate
Megan Meyers focuses on patent litigation, specifically Abbreviated New Drug Application (ANDA) matters at the district court level and in appeals to the U.S. Court of Appeals for the Federal Circuit. She has experience representing pharmaceutical patent holders in ANDA and 505(b)(2) application litigations arising under the Hatch-Waxman Act. Megan also has substantial litigation experience involving biologics and gene therapy treatments. Her practice spans all phases of patent litigation, including managing discovery; defending fact and expert depositions; developing patent infringement and validity arguments; writing post-trial briefs and dispositive motions; and preparing and examining witnesses at trial.
Megan holds leadership positions in various organizations, including serving as the vice chair of the Food & Drug Committee for the American Intellectual Property Law Association (AIPLA). She uses her knowledge of the Food & Drug Administration (FDA) and Orange Book procedures to assist in client counseling regarding these topics.
Prior to her legal career, Megan worked in a prosthetics and orthotics lab, where she gained experience with the fabrication of various medical devices. During law school, Megan completed a certificate program focused on advising biology Ph.D. students on intellectual property matters, including obtaining protection for their technologies and analyzing the commercialization of these innovative technologies. Megan also worked as an analyst for an angel investing group that evaluated startup companies for investment potential, including the strength of their patent portfolios.
Megan has a passion for pro bono work. While in law school, she worked with the Health Law Partnership, a branch of Atlanta Legal Aid that partners with impoverished families and children who are patients at Children’s Healthcare of Atlanta. Her work with these families included addressing landlord/tenant issues, Supplemental Security Income (SSI), disability, and family law matters. Megan also successfully represents injured veterans, including writing several briefs to file with the U.S. Court of Appeals for Veterans Claims on behalf of these veterans.
Promptu Systems Corporation v. Comcast Corporation
Obtained a $240 million jury verdict for client Promptu in a patent infringement lawsuit against Comcast. The jury found that Comcast willfully infringed Promptu’s patents covering voice recognition technology for TV.
2:16-cv-06516, E.D. Pa., Judge Sanchez
22-1939, Fed. Cir., Judges Prost, Moore, Taranto
Incyte Corporation et al. v. Sun Pharmaceutical Industries Limited et al.
Successfully represented Incyte in patent litigation, including preliminary injunction proceedings related to Sun Pharmaceuticals’ deuterated Janus kinase (JAK) inhibitor, LEQSELVI™. Case settled favorably for our client.
2:24-cv-06944, D.N.J., Judge Padin
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Successfully defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc.
1:18-cv-00664, D. Del., Judge Andrews
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Trial counsel for Novartis in district court litigation against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer. After a bench trial, the case resulted in a favorable settlement for our client, supporting patent protection at least until 2031.
1:21-cv-00870, D. Del., Judge Hall
Federal Circuit IP Blog
Federal Circuit Affirms-in-Part and Vacates-in-Part PTAB Unpatentability Findings Based on Claim Construction Federal Circuit Affirms-in-Part and Vacates-in-Part PTAB Unpatentability Findings Based on Claim Construction
October 27, 2025
Webinar
Patent Eligibility and Engineered Natural Products: Overcoming 101 Challenges, Leveraging Options for IP Protection Patent Eligibility and Engineered Natural Products: Overcoming 101 Challenges, Leveraging Options for IP Protection
April 17, 2025
Webinar
Award/Ranking
61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll 61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll
May 7, 2026
Media Mention
Comcast Hit With $240M Verdict in Voice Recognition IP Trial Comcast Hit With $240M Verdict in Voice Recognition IP Trial
January 27, 2026
Law360Award/Ranking
56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll 56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll
April 24, 2025
DC BarMedia Mention
NJ Judge Blocks Sun Pharma from Launching Hair Loss Drug NJ Judge Blocks Sun Pharma from Launching Hair Loss Drug
November 4, 2024
Law360Press Release
46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll 46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll
June 3, 2022
Media Mention
Litigators of the Week: Shout Out Litigators of the Week: Shout Out
October 22, 2021
The AmLaw Litigation DailyDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.